Phaseline

Targets › CEP290

CEP290 (Centrosomal protein of 290 kDa): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 2 Phase 3, 1 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Feb 2027.

Involved in early and late steps in cilia formation. Its association with CCP110 is required for inhibition of primary cilia formation by CCP110. (UniProt, O15078)

Open in Phaseline: the race on CEP290, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OcugenOCU400
Gene therapy vector for retinitis pigmentosa and Leber congenital amaurosis
RHO, NR2E3, CEP290Phase 3Retinitis PigmentosaFeb 2027
Laboratoires TheaSepofarsen (QR-110)
CEP290 mRNA positive modulator
CEP290Phase 3Leber Congenital Amaurosis 10Nov 2027
ProQR TherapeuticsSepofarsen (QR-110)
CEP290 mRNA positive modulator
CEP290Phase 2Leber Congenital Amaurosis 10–

Conditions

Leber Congenital Amaurosis 10 (2) Retinitis Pigmentosa (2)

Modalities

other (3)

Companies

Laboratoires Thea (1) ProQR Therapeutics (1) Ocugen (1)

Related targets

RHO (1) NR2E3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.